Myopathy in Statin-Treated Children and Adolescents: A Practical Approach

Area of Science:

• Pediatric pharmacology
• Clinical toxicology
• Cardiovascular therapeutics

Background:

• Statins are increasingly prescribed for pediatric dyslipidemia.
• Statin-associated myopathy is a known adverse effect in adults.
• Limited data exists on statin myopathy in pediatric populations.

Purpose of the Study:

• To review current literature on statin-related myopathy in children and adolescents.
• To guide the development of a practical management strategy for pediatric statin use.

Main Methods:

• Systematic literature review of studies on statin treatment in pediatric patients.
• Analysis of reported cases of myopathy, including creatine kinase (CK) levels and symptoms.
• Evaluation of randomized controlled trials (RCTs) comparing statin users and controls.

Main Results:

• Most pediatric statin use reports show no muscle pathology.
• Asymptomatic CK elevation and muscle pain without CK elevation occurred similarly in statin users and controls in RCTs.
• Rare cases of rhabdomyolysis have been reported in children on statins, a previously undocumented issue.

Conclusions:

• Statin-induced myopathy is infrequent in childhood.
• Routine CK monitoring in asymptomatic pediatric patients is not recommended.
• CK monitoring should be reserved for symptomatic patients; education on rhabdomyolysis symptoms (dark urine, muscle pain) is crucial for prompt medical intervention.